



Rescission of NC State Health Director's Standing Order Authorizing Intravenous Administration of Casirivimab/Imdevimab (REGEN-COV) Monoclonal Antibodies

I hereby rescind the standing order authorizing Intravenous Administration of Casirivimab/Imdevimab (REGEN-COV) Monoclonal Antibodies that was issued on January 5<sup>th</sup>, 2022 due to the high prevalence of the Omicron variant of SARS-CoV-2 virus in North Carolina for which REGEN-COV is not an effective treatment.

The rescission of this standing order shall not impact any actions taken in reliance on this standing order prior to the date of rescission.

A handwritten signature in black ink that reads "E. Cuervo Tilson".

Approved by: \_\_\_\_\_

Elizabeth Cuervo Tilson, MD, MPH  
NPI: 1760540421

Date Signed: 1-24-22\_\_\_\_\_